Comparison and validation of screening tools for substance use in pregnancy: A cross-sectional study conducted in Maryland prenatal clinics

BMJ Open

Volumn 8, Issue 2, 2018, Pages

  Coleman Cowger, Victoria H ^a   Oga, Emmanuel A ^a   Peters, Erica N ^a   Trocin, Kathleen ^a   Koszowski, Bartosz ^a   Mark, Katrina ^b  

^a BATTELLE MEMORIAL INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

4p's plus; biochemical verification; nida quick screen assist; pregnancy; substance use screening; surp p

Indexed keywords

AMPHETAMINE DERIVATIVE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CANNABIS; COCAINE; DEXTROPROPOXYPHENE; ILLICIT DRUG; METHADONE; METHAMPHETAMINE; OPIATE; OXYCODONE; PHENCYCLIDINE; PRESCRIPTION DRUG; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BIRTH WEIGHT; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG SCREENING; ELECTRONIC MEDICAL RECORD; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GESTATIONAL AGE; HAIR ANALYSIS; HEAD CIRCUMFERENCE; HUMAN; MAJOR CLINICAL STUDY; MARYLAND; NEONATAL INTENSIVE CARE UNIT; OBSTETRIC PATIENT; OBSTETRICS; PILOT STUDY; PREGNANCY; PREGNANCY OUTCOME; PRENATAL CARE; SCREENING TEST; SELF REPORT; SENSITIVITY AND SPECIFICITY; SPONTANEOUS ABORTION; STILLBIRTH; SUBSTANCE ABUSE; SUBSTANCE USE; TELEPHONE INTERVIEW; TEST RETEST RELIABILITY; URINALYSIS; URINE BIOCHEMISTRY; URINE SAMPLING; VALIDATION STUDY; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; DRUG DEPENDENCE; HAIR; MASS SCREENING; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; PREGNANCY COMPLICATION; PROCEDURES; REPRODUCIBILITY; STATISTICAL MODEL; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AMBULATORY CARE FACILITIES; CROSS-SECTIONAL STUDIES; FEMALE; HAIR; HUMANS; LOGISTIC MODELS; MARYLAND; MASS SCREENING; PILOT PROJECTS; PREGNANCY; PREGNANCY COMPLICATIONS; REPRODUCIBILITY OF RESULTS; SELF REPORT; SENSITIVITY AND SPECIFICITY; SUBSTANCE-RELATED DISORDERS; URINE; YOUNG ADULT;

EID: 85048575297     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2017-020248     Document Type: Article

References (10)

1. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2012 National Survey on Drug Use and Health: Summary of national findings. NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.
2. World Health Organization. Guidelines for the identification and management of substance use and substance use disorders in pregnancy, 2014.
3. Scholle SH, Kelleher K. Assessing primary care performance in an obstetrics/gynecology clinic. Women Health 2003;37:15-30.
4. ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012;119:79-80.
5. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction 2002;97:1183-94.
6. Smith PC, Schmidt SM, Allensworth-Davies D, et al. A singlequestion screening test for drug use in primary care. Arch Intern Med 2010;170:1155-60.
7. Chasnoff IJ, Wells AM, McGourty RF, et al. Validation of the 4P's Plus screen for substance use in pregnancy validation of the 4P's Plus. J Perinatol 2007;27:744-8.
8. Yonkers KA, Gotman N, Kershaw T, et al. Screening for prenatal substance use: development of the Substance Use Risk Profile-Pregnancy scale. Obstet Gynecol 2010;116:827.
9. Guttmacher Institute. State laws and policies: substance use during pregnancy. 2017 https://www. guttmacher. org/ state-policy/ explore/ substance-use-during-pregnancy (accessed 18 Dec 2017).
10. Knight KR. Addicted pregnant poor. North Carolina, US: Duke University Press, 2015.